Frequency of CYP2D6*3 and *4 and metabolizer phenotypes in three mestizo Peruvian populations

Angel T. Alvarado¹, Roberto Ybañez-Julca², Ana María Muñoz³, César Tejada-Bechi⁴, Roberto Cerro⁵, Luis Abel Quiñones⁶,⁸, Nelson Varela⁵,⁸, César André Alvarado⁶, Erick Alvarado⁶, María R. Bendezú⁵, Jorge A. García⁷

1 International Research Network in Pharmacology and Precision Medicine, Human Medicine, San Ignacio de Loyola University, Lima, Peru
2 Doctoral Program in Pharmacy and Biochemistry, National University of Trujillo, Trujillo, Peru
3 Research Unit in Nutrition, Functional Foods for Health and Nutraceuticals, San Ignacio de Loyola University, Lima, Peru
4 Hospital Santa Rosa, Lima, Peru
5 Laboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago de Chile, Chile
6 Faculty of Human Medicine, San Martin de Porres University, Lima, Peru
7 Faculty of Pharmacy and Biochemistry, San Luis Gonzaga National University of Ica, Ica, Peru
8 Latin American Network for the Implementation and Validation of Clinical Pharmacogenomics Guidelines (RELIVAF-CYTED), Madrid, Spain

Corresponding author: Angel T. Alvarado (eaa.alvarado@hotmail.com)

Received 14 September 2021 ♦ Accepted 11 November 2021 ♦ Published 8 December 2021

Citation: Alvarado AT, Ybañez-Julca R, Muñoz AM, Tejada-Bechi C, Cerro R, Quiñones LA, Varela N, Alvarado CA, Alvarado E, Bendezú MR, García JA (2021) Frequency of CYP2D6*3 and *4 and metabolizer phenotypes in three mestizo Peruvian populations. Pharmacia 68(4): 891–898. https://doi.org/10.3897/pharmacia.68.e75165

Abstract

Wild type genotypes (CYP2D6) and their allelic variants have been described in a sample of a Peruvian mestizo population. The global allele frequency was 0.015 for CYP2D6*3 and 0.051 for CYP2D6*4. The percentages of genotypes described were 97% CYP2D6*1/*1 and 3.0% CYP2D6*1/*3; 90.60% for CYP2D6*1/*1, 8.55% CYP2D6*1/*4 and 0.85% CYP2D6*4/*4. The allelic frequencies of CYP2D6*3 in the Lima subpopulations were 0.022 and 0.010 for Junin; CYP2D6*4 of 0.048, 0.060, and 0.050 for residents of Lima, Junin, and Tacna, respectively. The Hardy-Weinberg equilibrium test for the studied population showed that both frequencies are in equilibrium, p <.05. The metabolizer phenotype was inferred according to the genotypes: 11.54% were classified as intermediate metabolizers (*1/*3 or *1/*4) and 0.85% as poor metabolizers (*4/*4). It is concluded that the frequencies of the CYP2D6*3 and CYP2D6*4 alleles are low for the Peruvian mestizo population compared to the Latin American and tricontinental population, due to their natural population evolution, which is manifested by their decreased metabolic activity, the same that is relevant in clinical practice.

Keywords

Genetic polymorphism, Pharmacogenetics, Metabolic phenotype, Peruvian mestizo population
Introduction

Genetics is one of the main factors that determine the inter-ethnic variability in the pharmacological response, and this is explained by the differences in the population frequencies of genetic polymorphisms, which have clinical implications, therefore, the doses of a drug for a certain population, are not necessarily applicable to other populations or ethnic groups (Bertilsson, 1995); this polymorphism lies in the genes that encode various enzymes and among them, the family of the cytochrome P450 system, being the isoenzyme CYP2D6 (Debrisoquine 4-hydroxylase), the most representative in liver tissue (6% of all CYP450: CYP3A4, CYP2C9, and others) (Leitão et al. 2020), and is involved in the phase I metabolism of almost 25% of clinically important drugs (Zanger and Schwab 2013; Ray et al. 2019; Jessurun et al. 2020) and in the metabolism of carcinogens (Bradford 2002; Da Silva et al. 2009).

The CYP2D locus is made up of a gene cluster, a CYP2D6 gene, and two pseudogenes (CYP2D7 and CYP2D8), with 97% and 92% similarity, respectively (Kimura et al. 1989; Zhou 2009). The autosomal CYP2D6 gene is located on the long arm of chromosome 22 fragment q 13.1 (22q13.1), it consists of 4383 bp (Ur Rasheed et al. 2017) grouped in nine exons and eight introns that produces an mRNA of 1655 bp (Zanger et al. 2004; Dorado et al. 2017), with a 1383 bp open reading frame encoding a 497 amino acid protein (Salyakina et al. 2019; Leitão et al. 2020). More than 100 allelic variants have been described for this gene (https://www.pharmvar.org/gene/CYP2D6). Genes that have two functional alleles are called CYP2D6*1 and CYP2D6*2, which encode an enzyme with extensive functional activity or wild type (Flores-Angulo et al. 2015); the most frequent alleles in the different populations are CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6 (Rasheed et al. 2017) and CYP2D6*10 (Flores-Angulo et al. 2015), of which the most Common are CYP2D6*3 and * 4 (Da Silva et al. 2009) that express isoenzymes lacking activity (Johansson and Ingelman-Sundberg 2011; Flores-Angulo et al. 2015; Leitão et al. 2020). The CYP2D6*3 variant consists of a deletion of an adenine base at position 2549 (g.2549delA; rs35742686) of exon 5, causing a truncated protein (Kagimoto et al. 1990; Dorado et al. 2017; Ur Rasheed et al. 2017), CYP2D6*4 (g.1846G > A, rs3892097) is characterized by a single nucleotide polymorphism (transition from guanine to an adenine (G > A, rs1065852), expressing a protein with reduced activity (Flores-Angulo et al. 2015). To describe the phenotypes, age, sex, and nutritional status must be taken into account, however, it is a study carried out by Laires-Asseff et al. (2005) determined that there is no effect of the mentioned parameters on the phenotypic expression of CYP2D6 in Amerindian subjects of Tepehuan origin, using dextromethorphan as a metabolic marker, which may be due to the size of the population sample. Metabolic phenotypes can be obtained by extrapolating genotypes by putting the letter “g” in front of them to differentiate from phenotypes obtained with a test drug such as dextromethorphan (Llerena et al. 2014); thus we have genotypic extensive metabolizer (gEM), genotypic intermediate metabolizer (gIM), and genotypic poor metabolizer (gPM) (Gaedigk et al. 2008; Llerena et al. 2014).

After conducting a review in the PubMed-NCBI database on the studies of CYP2D6 in Peruvian populations, it is evident that they are still scarce, being necessary to study them, due to their European migratory origin (Hunley and Healy 2011) (mainly Spanish) (Vilchez 2016), Latin American, African (Hunley and Healy 2011; Hererra-Paz 2013), and Asian (Chinese and Japanese) (Vilchez 2016), which have generated the current miscegenation of Peruvians, 68.3% Latin American (Homburger et al. 2015), 26–29% European (Ruiz-Linares et al. 2014), 3.2% African and 2.5% Asian (Homburger et al. 2015). A high percentage (> 50%) of the mestizo population was observed in Lima, Tacna, and Junin (INEI 2018). Due to these considerations, we have decided to study CYP2D6*3 and CYP2D6*4 in populations of the three aforementioned provinces, the alleles being selected, as they are the most frequent in Latin American populations (Muñoz et al. 1998) and in the world (Da Silva et al. 2009), due to their population and interethnic variability and because they metabolize more 25% of drugs for clinical use (Sa-
mer et al. 2013; Salyakina et al. 2019; Leitão et al. 2020), mostly with a narrow therapeutic margin, so at standard doses with certain drugs, potential adverse effects (tricyclic antidepressants) can be observed, or absence of the pharmacological effect as in the case of codeine (Madadi and Koren 2008; Llerena et al. 2014).

Our objective was to identify the frequencies of the CYP2D6*3 (rs35742686) and CYP2D6*4 (rs3892097) variants to catalog the metabolic phenotypes of drugs in a sample of a Peruvian mestizo population, given their phenotypic importance as well as their high population and interethnic variability.

Materials and methods
Design, type of sampling and study population

Observational, descriptive, cross-sectional study, non-probabilistic convenience sampling and prospective recruitment between January 2017 and December 2020. The Peruvian inhabitants were summoned and informed about the objectives and importance of the study, after that, only those who signed the informed consent freely and voluntarily, were enrolled in the present investigation (Alvarado et al. 2019; Alvarado et al. 2021). A total of 234 Peruvian mestizo subjects (174, 74.36% men; 60 women, 25.64%) were recruited for this study; 184 were from the coastal zone of the Pacific Lima (n = 134; 57.26%) and Tacna (n = 50; 21.37%), and 50 subjects from the Andean zone of Junin (21.37%); and with an age of 19 to 53 years (mean of 24.68 years); both sexes [Lima: female 35 (26.12%); male 99 (73.88%); Tacna: female 9 (18%); male 41 (82%); Junin: female 16 (32%); male 34 (68%)] and with a mean age of 24.68 years (Lima: female, mean 26.63, SD ± 7.73; male, mean 23.72, SD ± 5.04. Tacna: female, mean 25.78, SD ± 2.33; male, mean 24.83, SD ± 3.04. Junin: female, mean 24.63, SD ± 1.63; male, mean 25, SD ± 0.65).

Inclusion and exclusion criteria

To include mestizo Peruvians in the present study, reports of the migratory pattern, native genes, and non-molecular markers of miscegenation (linguistic tree and surnames) were considered (Alvarado et al. 2021). Regarding the migratory pattern of Peruvians, this is a complex phenomenon, generated by the economic crisis, by the displacement of rural areas and the countryside towards the city, by natural disasters (Yamada 2010; Carrillo-Larco et al. 2017), and in the case of young people, it is due to the aspiration to pursue university studies, improve their social and economic level and living conditions, which contributes to the internal miscegenation of Peruvians (Carrillo-Larco et al. 2017), at the same time, said miscegenation, is due to migration of Latin Americans, Europeans, Africans (Hunley and Healy 2011), and Asians to Peru (Vilchez 2016); considering the linguistic tree and the ancestry surnames, which indicate the migratory pattern, population structure and historical phylogenetic relationships between populations (Herrera-Paz 2013). At the same time, it has been reported that 60%-70% of Peruvians have native genes that classify them as mestizos (Harris et al. 2018), observing in Lima 67.7% of the mestizo population and 2.8% of Afro-Peruvians; in Tacna (coastal border and commercial province) 49.3% are mestizo, 32.9% Aymara and 1.7% Afro-Peruvian; Junin (Andean zone) 52.4% are mestizo, 34.9% Quechua, 0.2% Aymara and 0.5% Afro-Peruvian (INEI 2018).

All of this allowed us to select mestizo Peruvians over 18 years of age and of coastal and Andean origin; at the medical examination, be in good health (systolic blood pressure of 110–139 mm Hg and diastolic of 60–89 mm Hg, abdominal circumference less than 95 cm in men and 82 cm in women and not having a diagnosis of diabetes); and by an explicit declaration of each volunteer not to consume alcoholic beverages or drugs of abuse, not to have a difficulty that prevents the taking of the biological sample and to give their consent in writing. All subjects, who belonged to an ethnic group, were not in a position to give their consent, and those who did not meet the inclusion criteria were excluded from the study (Alvarado et al. 2019; Alvarado et al. 2021).

Obtaining genomic DNA

Genomic DNA (gDNA) was obtained by buccal swabbing of non-keratinized stratified epithelial tissue, rubbing the inner cheek mucosa five to six times with the swab to ensure an adequate amount of scaly cells. Subsequently, the swab was immersed for 60s in 300 µL of lysis buffer and the resulting mixture was refrigerated at 4°C for a time not exceeding 18 hours. The DNA was extracted using the innuPRE DNA Master kit (Analytik Jena), following the manufacturer’s protocol, a procedure performed at the USIL Pharmacology Laboratory. Genomic DNA was quantified by spectrophotometry using Denovix equipment (model DS-11, FX, Spectrophotometer Series, USA). Samples with absorbance ratios of 260/280 nm and 260/230 nm equal to or greater than 1.8 were considered suitable for the study. The samples were stored at -20°C until analysis.

Genotypic analysis

The genotypes were determined using the real-time PCR technique (RT-PCR), using Buffer TE 1X reagents, for the identification of allelic variants, TaqMan probes capable of discriminating single nucleotide polymorphisms (SNPs) identified as CYP2D6*3 (rs35742686) and CYP2D6*4 (rs3892097) (TaqMan Genotyping Master Mix, catalog number 4371355-brand Thermo Fischer Scientific Inc.). The CYP2D6*1 allele was not directly determined; All alleles that were negative for SNPs CYP2D6*3 and CYP2D6*4 were designated as CYP2D6*1, which is acceptable when the sequence variations corresponding to alleles are not determined, so it is not wrong to assume that No *X = *1.
In the standard protocol, the reaction mix was 20 ng gDNA, 5 µL of 2X Genotyping Master Mix (Catalog No 4371355), 0.5 µL of 20X TaqMan SNP Genotyping Assay (containing the two probes and primers direct and reverse) and nuclease-free molecular biology grade water (HyPure HyCloneTM) in sufficient quantity for 10 µL of final reaction volume.

To determine CYP2D6*3, the TaqMan SNP Genotyping Assay catalog number 4362691 was used; C_32407232_50, which discriminates the g.2549delA deletion; and for CYP2D6*4 the catalog number 4362691; C_27102431_ D0, which discriminates the transition g.1846G > A.

For the amplification, the Stratagene Mx3000P equipment (Agilent Technologies, Waldbronn, Germany) was used, whose program consisted of an initial cycle of denaturation at 95°C for 10 min, and the second segment consisted of 50 cycles consisting of 15 s of denaturation at 92°C, 90 s of alignment at 60°C and 60 s of elongation at 72°C.

**Statistical analysis**

To determine if the distribution of the studied genotypes was in Hardy-Weinberg equilibrium (HWE), the Chi-square (X²) goodness-of-fit test was performed, considering a degree of freedom and a p-value <0.05. X² values less than 3.88 in the comparison indicated acceptance of the null hypothesis, therefore, the observed frequencies did not differ significantly from those expected (Alvarado et al. 2019; Alvarado et al. 2021). CYP2D6 allele frequencies predicted metabolic phenotypes (Zanger et al. 2004). The Statistical Software GraphPad Prism 9 was used. Version 9.1.2.

**Ethical considerations**

The study was carried out in strict compliance with good clinical practices (BCP), Code of Ethics of the World Medical Association (Declaration of Helsinki), the research protocol, and informed consent being approved by the Ethics Committee of Hospital Santa Rosa, by certificate No 16-19-CMI-HSR. Each volunteer was assigned a code number to guarantee their anonymity and confidentiality (Alvarado et al. 2019; Alvarado et al. 2021).

**Results**

Table 1 shows that the frequency of the CYP2D6*4 allele is higher than the CYP2D6*3 allele (0.015), while the wild-type genotype and allele frequencies are the most frequent, for a sample of Peruvian mestizo inhabitants. No homozygous *3/*3 (del/del) genotypes were described in these populations.

Next, the genotype and allelic frequencies of the sub-samples corresponding to inhabitants of the coast and the Andes of Peru are exposed, which are low. For Lima residents, the frequency of CYP2D6*1/*3 and *3/*3 is 0.022, and for Junin it is 0.01, but they were not observed in Tacna residents; while the frequency of CYP2D6*1/*4 and *4/*4 was similar in the three provinces (Table 2).

Table 3 shows the phenotypes that can be extrapolated from the genotypes, observing in this group of the mestizo population 12.39% of metabolic phenotypes with decreased activity, of which 0.85% are poor metabolizers.

Figure 2 shows the percentages of extrapolated poor metabolizers (gPM) of CYP2D6 from the European, A-

**Table 1.** Genotype frequencies for alleles *3 and *4 of the CYP2D6 gene in a sample of a Peruvian mestizo population.

| Reference ID | Genotype | Nucleotide | n (%) | Allele | t | X² |
|--------------|----------|------------|-------|--------|---|----|
| rs35742688   | *1/*1    | A/A        | 227    | 97.0   | *3 | 0.952 |
|              | *1/*3    | A/del      | 7      | 3.0    | *3 | 0.015 0.054 |
|              | *3/*3    | del/del    | 0      | 0.0    |    |    |
| Total        |          |            | 234    | 100.0  |    |    |
| rs2892097    | *1/*1    | G/G        | 212    | 90.6   | *1 | 0.949 |
|              | *1/*4    | G/A        | 20     | 8.55   | *4 | 0.051 3.46 |
|              | *4/*4    | A/A        | 2      | 0.85   |    |    |
| Total        |          |            | 234    | 100.0  |    |    |

n: sample number, %: percentage, t: allelic frequency.

**Table 2.** Genotypic and allelic frequencies for the variants *3 and *4 of the CYP2D6 gene in the three Peruvian mestizo populations included in the present study.

| Genotype    | Lima (n, %) | Tacna (n, %) | Junin (n, %) | Allelic frequency |
|-------------|-------------|--------------|--------------|-------------------|
| CYP2D6*5/*1 | 128 (95.5)  | 50 (100.0)   | 49 (98.0)    | 0.978 1.0 0.99 |
| CYP2D6*2/*3 | 6 (4.5)     | 0 (0.0)      | 1 (2.0)      | 0.022 0.0 0.01 |
| CYP2D6*3/*3 | 0 (0.0)     | 0 (0.0)      | 0 (0.0)      |        0.00 0.00 |
| Total       | 134 (100.0) | 50 (100.0)   | 50 (100.0)   | 1.00 1.00 1.00 |
| CYP2D6*7/*1 | 121 (93.0)  | 45 (90.0)    | 44 (88.0)    | 0.952 0.95 0.94 |
| CYP2D6*8/*4 | 13 (9.7)    | 5 (10.0)     | 4 (8.0)      | 0.048 0.05 0.06 |
| CYP2D6*9/*4 | 0 (0.0)     | 0 (0.0)      | 2 (4.0)      |        0.02 0.04 |
| Total       | 134 (100.0) | 50 (100.0)   | 50 (100.0)   | 1.00 1.00 1.00 |

n: sample number by province, %: percentage of genotypes by province.

**Table 3.** Extrapolated metabolic phenotypes in the Peruvian mestizo population, according to the combinations of CYP2D6*3 and *4.

| Extrapolated    | CYP2D6*3   | CYP2D6*4   | Activity | n (%) | Genotypes |
|-----------------|------------|------------|----------|-------|-----------|
| Extensive       | 1*1/1      | 1*1/1      | 2/2      | 205   | 87.61     |
| Intermediate    | 1*1/3      | 1*1/1      | 0.5–1.5  | 7     | 11.54     |
| Poor            | 1*1/1      | 4*4/4      | 0.85     | 4*4/4 |

n: sample number, %: percentage of metabolizers.

**Table 4.** Studies of CYP2D6*3 and *4 in Latin American and tricontinental populations were used in the comparison with the Peruvian population studied.

| Population       | CYP2D6*3(n) | CYP2D6*4(n) | Reference    |
|------------------|-------------|-------------|--------------|
| Mestizo Peruvian | 3.0(234)    | 9.4(324)    | Present study|
| Costa Ricans     | 1.0(139)    | 10.0(130)   | Cispedes-Garrio et al. 2014 |
| Colombians       | 1.2(121)    | 10.4(121)   | Isaza et al. 2000 |
| Brazilians       | 3.4(89)     | 17.8(89)    | Da Silva et al. 2009 |
| Chileans         | 1.0(253)    | 12.0(253)   | Roco et al. 2012 |
| Ecuadorians      | 0.4         | 10.6(118)   | Dorado et al. 2012 |
| Africans         | 0           | 0.0         | Quíntones et al. 2017 |
| East Asians      | 0           | 0.0         | Quíntones et al. 2017 |
| South Asians     | 0           | 0.0         | Quíntones et al. 2017 |
| European         | 2           | 19.0        | Quíntones et al. 2017 |
| Spanish people   | 1(105)      | 13.6(105)   | Menoyo et al. 2006 |
Table 4 shows the percentages of CYP2D6*3 and *4 of the populations that originate the miscegenation of Peruvians, the same that is tricontinental (European, African, and Asian) and Latin American.

**Discussion**

In this study, the CYP2D6*3 and CYP2D6*4 alleles were characterized in samples of 234 mestizo inhabitants of the coastal zone (Lima and Tacna) and the Andean Province (Junín) of Peru. Observing 3% of the CYP2D6*3 genotype and 9.4% of CYP2D6*4; with a frequency of the allele CYP2D6*3 and CYP2D6*4 of 0.015 and 0.051, respectively. In previous Latin American studies on CYP2D6*3 it has been reported that this genotype is rare and varies from 0.4% to 2.0%. In Europeans, it is 2% (Quiñones et al. 2017) and exclusively in the Spanish population, it is 1% (n = 105) (Menoyo et al. 2006); while, in Africans and Asians, the frequency is 0% (Quiñones et al. 2017). The X² for both polymorphisms indicates that the observed genotype frequencies did not differ significantly from those expected, so there is an HWE. This research shows a difference in frequencies with the Latin American populations, having a greater similarity with the Costa Ricans (Céspedes-Garro et al. 2014), Ecuadorians (Dorado et al. 2012), and Colombian populations (Isaza et al. 2000). The percentage is higher in Spanish populations (Menoyo et al. 2006), lower in Africans, and not expressed in East Asians (Quiñones et al. 2017). This is due to the natural evolution suffered by populations since more than 488 years have passed since the arrival of the first Spaniards (1532), Africans (1527), Chinese (1849), and Japanese (1899) (Vilchez 2016). Ingelman-Sundberg M (2005) explains that the difference in the distribution of CYP2D6 alleles is due to the evolutionary peculiarities of the populations, which is evidenced by metabolic variability; also, it has been established that the frequencies of allelic variants are different in each ethnic group, but the effect of each allelic variant is identical in all populations (Zanger et al. 2004).

Regarding the extrapolated phenotypes, it is observed that 11.54% are genotypic intermediate metabolizers (gIM) with mutated heterozygous genotypes *1/*3 and *1/*4; while 0.85% are genotypic poor metabolizers (gPM) with an activity of 0.5–1.5 and 0, respectively (Gaedigk et al. 2008; Llerena et al. 2014); the gPMs of the present study have a greater similarity with those reported for Ecuadorians, followed by Brazilians, and in terms of continental ancestry, there is a greater similarity with Africans (Ensemble). In a study carried out by Sosa-Macias et al. (2006), it was shown that the frequency of the poor metabolizer phenotype in Mexican mestizos was 6.8%, and in Tepehuan Amerindians they were not observed.

These results are relevant in clinical practice for this group of the mestizo population, as they are susceptible to presenting side effects and even adverse reactions, since the drug not metabolized by the CYP2D6 protein, exceeds the maximum effective plasma concentration (C₇ME), being necessary to adjust dose based on phenotype and follow pharmacotherapy.

The limitations of the present study are in the sample size and in the method of selection for convenience. Anoth-
er bias, which can lead to confusion, is not having studied the other allelic variants of CYP2D6, which are being considered in future studies by our research network. In our country, pharmacogenetic studies are still limited, although there is evidence in other Latin American countries that shows that they influence the safety and efficacy of drugs. Notwithstanding the foregoing, the results presented in this study are relevant, as they contribute to generating scientific evidence and encourage clinical studies in precision medicine, especially in patients who are treated with drugs with a narrow therapeutic margin such as antidepressants, angesics, opioids, anti hypertensives (metoprolol, propranolol), antiarrhythmics (propafenone and quinidine), neuroleptics, docetaxel, paclitaxel, tamoxifen, and tamsulosin (Zanger and Schwab 2013; Ray et al. 2019; Jessurun et al. 2020).

We recommend conducting more research on these other CYP2D6 alleles to complement the present study and promote them as biomarkers in precision medicine in underserved populations in Peru.

Our findings indicate that the average frequencies of the CYP2D6*3 and CYP2D6*4 alleles are low for the Peruvian mestizo population compared to the Latin American and tricontinental populations, due to their natural population evolution, which is manifested by their activity decreased metabolism, the same that is relevant in clinical practice, since CYP2D6 intervenes in the metabolism of a wide variety of prescription drugs.

The interpopulation variability reported in previous Latin American studies supports the need for large-scale pharmacogenetic studies in our country.

Acknowledgements

Latin American Society of Pharmacogenomics and Personalized Medicine and Latin American Network for the Implementation and Validation of Clinical Pharmacogenomics Guidelines (RELIVAF-CYTTE), Madrid, Spain.

Conclusion

References

Alvarado AT, Muñoz AM, Loja B, Mijasato JM, García JA, Cerro RA, Quiñones LA, Varela NM (2019) Estudio de las variantes alélicas CYP2C9*2 y CYP2C9*3 en muestras de población mestiza peruana. Biomedica. 39(3): 601–610. https://doi.org/10.7705/biomedica.4636

Alvarado AT, Muñoz AM, Saravia M, Valderrama-Wong M, González D, Quiñones L, Varela N, Borrero M, García-Devalle J, Loja-Herre B (2021) Frequency of CYP1A1*2A polymorphisms and deletion of the GSMT1 gene in a Peruvian mestizo population. Pharmacia. 68(4): 747–754. https://doi.org/10.3897/pharmacia.68.e7162

Bertilsson L (1995) Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clinical Pharmacokinetics. 29(3): 192–209. https://doi.org/10.2165/00003088-199529030-00005

Bradford LD (2002) CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 3(2): 229–243. https://doi.org/10.1517/14622416.3.2.229

Carrillo-Larco RM, Ruiz-Alejos A, Bernabé-Ortiz A, Gilman RH, Smeeth L, Miranda JJ (2017) Cohort Profile: The PERU MIGRANT Study-A prospective cohort study of rural dwellers, urban dwellers and rural-to-urban migrants in Peru. International Journal of Epidemiology. 46(6): 1752–1752F. https://doi.org/10.1093/ije/dyx116

Céspedes-Garro C, Jiménez-Arce G, Naranjo ME, Barrantes R, Llerena A, CEIBA.FP Consortium of the Ibero-American Network of Pharmacogenetics & Pharmacogenomics RIEF (2014) Ethnic background and CYP2D6 genetic polymorphisms in Costa Ricans. Revista de Biología Tropical. 62(4): 1659-1671.

Da Silva V, Canalle R, Scrideli CA, Gomes de Paula R, Gonzaga L (2009) Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes in a Brazilian population. Biomarkers 14(2): 111–117. https://doi.org/10.1080/1354700902767294

De Andrés F, Sosa M, Lazáde B, Naranjo ME, Llerena A (2017) CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indig enous Populations-Where to from Here for Global Precision Medicine? Journal of Integrative Biology. 21(9): 509–519. https://doi.org/10.1089/omi.2017.0101

Dorado P, Heras N, Machín E, Hernández F, Terán E, Llerena A (2012) CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population. European Journal of Clinical Pharmacology. 68(5): 637–644. https://doi.org/10.1007/s00228-011-1147-8

Dorado P, González I, Naranjo ME, de Andés F, Peñas-Lledó EM, Calzadilla LR, LLerena A (2017) Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism. OMICS: A Journal of Integrative Biology. 21(1): 17–26. https://doi.org/10.1089/omi.2016.0166

Ensemble. rs3892097 SNP. https://www.ensembl.org/Multi/Search/Results?f=r=rs3892097%20SNP [Accessed September 6, 2021].

Flores-Angulo C, Villegas C, Mora Y, Martínez J, Oropeza T, Moreno N (2015) Variantes alélicas de CYP2D6: ‘*4, ‘*6 y ‘*10 en una muestra de residentes del Estado de Aragua, Venezuela. Revista Peruana de Medicina Experimental y Salud Pública. 32(4): 746–751.

Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS (2008) The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clinical Pharmacology & Therapeutics. 83(2): 234–242. https://doi.org/10.1038/sj.clpt.6100406

Griman P, Moran Y, Camargo M, Chiurillo MA (2009) Caracterización de variantes alélicas de citocromo CYP2D6 en la población de la región centrooccidental de Venezuela. Acta Biológica Colombiana. 14(1): 195–202.

Griman P, Moran Y, Valero G, Loreto M, Borjas L, Chiurillo MA (2012) CYP2D6 gene variants in urban/admixed and Amerindian populations of Venezuela: pharmacogenetics and anthropological implications. Annals of Human Biology. 39(2): 137–142. https://doi.org/10.3109/03014460.2012.656703
Harris DN, Song W, Shetty AC, Levano KS, Cáceres O, Padilla C, Borda V, Tarazona D, Trujillo O, Sanchez C, Kessler MD, Galarza M, Capristano S, Montejo H, Flores-Villanueva PO, Tarazona-Santos E, O'Connor TD, Guio H (2018) Evolutionary genetic dynamics of Peruvians before, during, and after the Inca Empire. Proceedings of the National Academy of Sciences of the United States of America 115(28): E6526-E6535. https://doi.org/10.1073/pnas.1720798115

Herrera-Paz E (2013) La genética de poblaciones y el origen de la diversidad humana. Rev Med Mundial 81(1): 40–45.

Homburger J, Moreno-Estrada A, Gignoux C, Nelson D, Sanchez E, Ortiz-Tello P, Pons-Estel BA, Acevedo-Vasquez E, Miranda P, Langelfd CD, Gravel S, Alarcon-Riquelme ME, Bustamante CD (2015) Genomic Insights into the Ancestry and Demographic History of South America. PloS Genetics 11(12): e1005602. https://doi.org/10.1371/journal.pgen.1005602

Hunley K, Healy M (2011) The impact of founder effects, gene flow, and European admixture on native American genetic diversity. The American Journal of Biological Anthropology. 146(4): 530–538. https://doi.org/10.1002/ajpa.21506

Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. The Pharmacogenomics Journal 5: 6–13. https://doi.org/10.1038/sj.tpj.6500285

INEI (2018) Resultados definitivos. Instituto Nacional de Estadística e Informática, INEI https://www.inei.gob.pe/media/MenuRecursivo/publicaciones_digitales/Est/Lib1544/00TOMO_01.pdf [Accessed July 15, 2021]

Isaza CA, Henao J, Lopez AM, Cacabelos R (2000) Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the colombian population. Methods Find Exp Clin Pharmacol 22(9): 695–705. https://doi.org/10.1258/mf.2000.22.9.082286

Jessurun NT, Wijnen PA, Bast A, van Puijenbroek EP, Bekers O, Drent ML (2012) Isolation, sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. The American Journal of Human Genetics. 45(6): 889–904.

Johansson I, Ingelman-Sundberg M (2011) Genetic polymorphism and toxicity-with emphasis on cytochrome p450. Toxicological Sciences. 120(1): 1–13. https://doi.org/10.1093/toxsci/kfq374

Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA (2000) Multi-alleles of the human cytochrome P450IIId6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. Journal of Biological Chemistry. 265(28): 17209–17214.

Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ (1989) The human debrisoquine 4-hydroxylase (CYP2D6) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. The American Journal of Human Genetics. 45(6): 898–904.

Letálo LP, Souza TP, Rodrigues JC, Fernandes MR, Santos S, Santos NP (2020) The Methabolization Profile of the CYP2D6 Gene in Amerindian: A Review. Genes 11(3): e262. https://doi.org/10.3390/genes11030262

Lares-Asseff I, Sosa-Macias M, Elizondo-Azuela G, Flores-Pérez C, Flores-Pérez J, Bradley-Alvarez F (2005) Phenotypic expression of CYP2D6 in amerindians of tepetlahua origin from Durango, Mexico. Proceedings of the Western Pharmacology Society. 48: 102–107.

Lu Y, Mo C, Zeng Z, Chen S, Xie Y, Peng Q, He Y, Deng Y, Wang J, Xie L, Zeng J, Li S, Qin X (2013) CYP2D6*4 Allele Polymorphism Increases the Risk of Parkinson’s Disease: Evidence from Meta-Analysis. PLoS ONE 8(12): e84413. https://doi.org/10.1371/journal.pone.0084413

Llerena A, Dorado P, Peñas-Lledó EM, Cáceres MC, De la Rubia A (2007) Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. The Pharmacogenomics Journal 7(6): 408–410. https://doi.org/10.1038/tpj.2005.49

Llerena A, Dorado P, Ramírez R, González I, Alvarez M, Peñas-Lledó EM, Pérez B, Calzadilla LR (2012) CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans. The Pharmacogenomics Journal 12(2):176–183. https://doi.org/10.1038/tpj.2010.85

Llerena A, Dorado P, Naranjo ME, Peñas-Lledó EM (2014) CYP2D6 ethnic variability in Hispanics. Future Medicine 4: 54–66. https://doi.org/10.2217/fmeb2013.13.139

Madadi P, Koren G (2008) Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. Pharmacogenomics 9(9): 1267–1284. https://doi.org/10.2217/14622416.9.9.1267

Menoyo A, del Rio E, Baiget M (2006) Characterization of variant alleles of cytochrome CYP2D6 in a Spanish population. Cell Biochem Funct 24(5): 381–385. https://doi.org/10.1002/cbf.1258

Muñoz S, Villoth V, Vallejos MP, Mújica JF, Covarrubias C, Raddatz A, Chianale J (1998) Genetic polymorphisms of CYP2D6, CYP1A1 and CYP2E1 in the South-American population of Chile. Pharmacogenetics 8(4): 343–351. https://doi.org/10.1097/00008571-199808000-00008

Perez-Paramo YX, Hernandez-Caberra F, Dorado P, Llerena A, Muñoz-Jimenez S, Ortiz-Lopez R, Rojas-Martinez A (2015) Interethnic relationships of CYP2D6 variants in native and Mestizo populations sharing the same ecosystem. Pharmacogenomics 16: 703–712. https://doi.org/10.2217/pgs.15.24

Quiñones L, Roco A, Cayún J, Escalante P, Miranda C, Varela N, Meneses F, Gallegos B, Zaruma-Torres F, Lares-Asseff I (2017) Farmacogenómica como herramienta fundamental para la medicina personalizada: aplicaciones en la práctica clínica. Revista Médica de Chile 145(4): 483–500. http://dx.doi.org/10.4067/S0034-9887201700400009

Ray B, Oztacag I, Sadee W, Wang D (2019) CYP2D6 haplotypes with enhancer SNP rs5758550 and rs16947 (*2 allele): implications for CYP2D6 genotyping panels. Pharmacogenet Genomics 29(2): 39–47. https://doi.org/10.1007/FPC.0000000000000363

Roco A, Quiñones L, Agüinde JA, García-Martín E, Squicciarini V, Miranda C, Garay J, Escalante P, Miranda C, Ibarra C, Varela N (2012) Frequencies of 23 functionally significant variant alleles in the National Academy of Sciences of the United States of America July 15, 2021

Ruiz-Linares A, Adhikari K, Acuña-Alonzo V, Quinto-Sanchez M, Jaén H, Oosterhuis W, Menoyo A, Ortiz-Tello P, Pons-Estel BA, Acevedo-Vasquez E, Garay J, Farfán N, Saavedra I, Cáceres D, Ibarra C, Varela N (2012) Frequencies of 23 functionally significant variant alleles of the human cytochrome P-450 2D6 (CYP2D6) gene in the Colombian population: comparison with Caucasian and Asian populations. Front Genet 3(229):1–9.

Salyakina D, Roy S, Wang W, Oliva M, Akhouri R, Sotto I, Mulas N, Solano R, Fernández JR, Sanchez S, Shamshad U, Perlyn C, McCafferty-Fernandez J (2019) Results and challenges of Cytochrome
P450 2D6 (CYP2D6) testing in an ethnically diverse South Florida population. Molecular Genetics & Genomic Medicine 7 :e922. https://doi.org/10.1002/mgg3.922

Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA (2013) Applications of CYP450 Testing in the Clinical Setting. Mol Diagn Ther 17: 165–184. https://doi.org/10.1007/s40291-013-0028-5

Saravia M, Losno R, Valderrama-Wong M, Muñoz AM, Bendezú M, García J, Surco F, Basurto P, Pineda-Pérez M, Alvarado AT (2021) Interacciones farmacocinéticas de la azitromicina e implicación clínica. Revista Cubana de Medicina Militar 50(3): e02101284.

Sosa-Macías M, Elizondo G, Flores-Pérez C, Flores-Pérez J, Bradley-Alvarez F, Alanis-Bañuelos RE, Lares-Asseff I (2006) CYP2D6 genotype and phenotype in Amerindians of Tepehuan origin and Mestizos of Durango, Mexico. The Journal of Clinical Pharmacology. 46(5): 527–536. https://doi.org/10.1177/0091270006287586

Ur Rasheed MS, Mishra AK, Singh MP (2017) Cytochrome P450 2D6 and Parkinson’s Disease: Polymorphism, Metabolic Role, Risk and Protection. Neurochemical Research. 42(12): 3353–3361. https://doi.org/10.1007/s11064-017-2384-8

Vilchez H (2016) Hacia una nueva diversidad: Migraciones asiáticas en América Latina. Tiempo y Espacio 26(65): 99–119.

Yamada G (2010) Patrones de migración interna en el Perú reciente. Centro de Investigación, Universidad del Pacífico, Lima, 34 págs.

Zanger UM, Raimundo S, Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Arch Pharmacol 369: 23–27. https://doi.org/10.1007/s00210-003-0832-2

Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics. 138(1):103–141. https://doi.org/10.1016/j.pharmthera.2012.12.007

Zhou SF (2009) Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance. Clinical Pharmacokinetics. 48 (11): 689–723. https://doi.org/10.2165/11318030-000000000-00000